Accentia Biopharmaceuticals Announces Option Agreement With Mayo Foundation On Patented Treatment Using Intranasal Antifungals For Chronic Sinusitis
12/15/2005 12:50:02 PM
TAMPA, Fla.--(BUSINESS WIRE)--Dec. 15, 2005--Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) announced today that it has signed an option agreement with the Mayo Foundation for Medical Education and Research for the exclusive right to negotiate a license for a method of use for any and all antifungals other than amphotericin B applied intranasally for the treatment of chronic sinusitis, sometimes known as chronic rhinosinusitis. If unexercised, the option expires on December 6, 2006. Accentia has previously obtained a worldwide exclusive license for the method of use, utilizing the antifungal, amphotericin B, for this indication. Accentia is developing a unique formulation of amphotericin B for intranasal application for the treatment of chronic sinusitis under an Investigational New Drug Application (IND).
comments powered by